Your browser doesn't support javascript.
loading
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications.
Kihlberg, Kristina; Baghaei, Fariba; Bruzelius, Maria; Funding, Eva; Holme, Pål Andre; Lassila, Riitta; Martin, Myriam; Nummi, Vuokko; Ranta, Susanna; Strandberg, Karin; Andersson, Nadine Gretenkort; Berntorp, Erik; Astermark, Jan.
Afiliação
  • Kihlberg K; Clinical Coagulation Research, Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Hematology, Oncology and Radiation Physics, Center for Thrombosis and Hemostasis, Skåne University Hospital, Malmö, Sweden. Electronic address: kristina.kihlberg@med.lu.se.
  • Baghaei F; Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Bruzelius M; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Funding E; Department of Hematology, Rigshospitalet, Copenhagen, Denmark; Institute of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
  • Holme PA; Department of Hematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Lassila R; Department of Hematology, Coagulation Disorders Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Martin M; Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Coagulation, University and Regional Laboratories Region Skåne, Malmö, Sweden.
  • Nummi V; Department of Hematology, Coagulation Disorders Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Ranta S; Pediatric Coagulation, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
  • Strandberg K; Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Coagulation, University and Regional Laboratories Region Skåne, Malmö, Sweden.
  • Andersson NG; Department of Hematology, Oncology and Radiation Physics, Center for Thrombosis and Hemostasis, Skåne University Hospital, Malmö, Sweden; Department of Clinical Sciences and Pediatrics, Lund University, Lund, Sweden; Department for Pediatric Hematology and Oncology, Skåne University Hospital, Lund,
  • Berntorp E; Clinical Coagulation Research, Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Astermark J; Clinical Coagulation Research, Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Hematology, Oncology and Radiation Physics, Center for Thrombosis and Hemostasis, Skåne University Hospital, Malmö, Sweden.
Thromb Res ; 217: 22-32, 2022 09.
Article em En | MEDLINE | ID: mdl-35842956
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemofilia B / Hemofilia A Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Thromb Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemofilia B / Hemofilia A Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Thromb Res Ano de publicação: 2022 Tipo de documento: Article